Skip to main content

Funding and History


The Institute for Medical Innovation was established in December 2008 with an $8.1 million five-year seed grant by The Ewing Marion Kauffman Foundation and an $8 million match from KU Endowment. 

Each year, IAMI supports millions of dollars of research for a healthier population and creates more than $1 billion dollars for the regional economy.

  • IAMI has invested more than $7.9 million in 48 drug, diagnostic, and medical device projects in partnership with research investigators across institutions and organizations. Seven projects receiving IAMI investment have been associated with royalty-bearing license agreements, with two technologies moving into Kansas-based startup companies led by former IAMI fellows and their faculty mentors.
  • IAMI's first commercial product, Epaned TM, developed in partnership with Silvergate Pharmaceuticals Inc. and Children's Mercy Kansas City, was approved by the FDA and launched in 2013.
  • IAMI's collaborations with industry, academia, government and disease philanthropy partners have supported advancement of 10 promising cancer treatments to clinical proof-of-concept trials over the past 6 years.
  • IAMI has supported more than $73 million in new federal funding awarded to regional stakeholder institutions and researchers, and currently supports more than $50 million in ongoing research. 
  • IAMI actively partners with regional assets in contract drug development (more than 9,000 employees work for over 100 companies and contribute greater than $1 billion to the regional economy each year) to advance drug, diagnostic and medical device projects from the bench to bedside. 

Last modified: Jul 26, 2018

The Kauffman grant awarded to KU represents an outcome of lessons learned by Kauffman from the evaluation of existing proof of concepts centers.

The IAMI model was created to incorporate and build upon best practices as defined by the Kauffman Foundation's research and programmatic initiatives.

The IAMI concept was proposed to the Kauffman Foundation Board of Trustees in mid-2008 and subsequently approved in December 2008.